Vistagen Therapeutics, Inc. SEC filings VTGN

Vistagen Therapeutics, Inc. has 908 filings in SEC EDGAR's recent list, going back to Sep 11, 2007. Its latest annual report, Form 10-K, was filed on Jun 15, 2026 for the period ended Mar 31, 2026. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 30, 2026 (exit or restructuring costs, other events). The company's fiscal year ends on March 31.

Form Description Filed Period
10-Q Quarterly report Aug 14, 2026 Jun 30, 2026
10-Q Quarterly report Feb 12, 2026 Dec 31, 2025
10-Q Quarterly report Nov 13, 2025 Sep 30, 2025
10-Q Quarterly report Aug 7, 2025 Jun 30, 2025
10-Q Quarterly report Feb 13, 2025 Dec 31, 2024
10-Q Quarterly report Nov 7, 2024 Sep 30, 2024
10-Q Quarterly report Aug 13, 2024 Jun 30, 2024
10-Q Quarterly report Feb 13, 2024 Dec 31, 2023
10-Q Quarterly report Nov 9, 2023 Sep 30, 2023
10-Q Quarterly report Aug 10, 2023 Jun 30, 2023
10-Q Quarterly report Feb 7, 2023 Dec 31, 2022
10-Q Quarterly report Nov 10, 2022 Sep 30, 2022
10-Q Quarterly report Aug 11, 2022 Jun 30, 2022
10-Q Quarterly report Feb 10, 2022 Dec 31, 2021
10-Q Quarterly report Nov 10, 2021 Sep 30, 2021
10-Q Quarterly report Aug 12, 2021 Jun 30, 2021
10-Q Quarterly report Feb 11, 2021 Dec 31, 2020
10-Q Quarterly report Nov 12, 2020 Sep 30, 2020
10-Q Quarterly report Aug 13, 2020 Jun 30, 2020
10-Q Quarterly report Feb 13, 2020 Dec 31, 2019
10-Q Quarterly report Nov 7, 2019 Sep 30, 2019
10-Q Quarterly report Aug 13, 2019 Jun 30, 2019
10-Q Quarterly report Feb 12, 2019 Dec 31, 2018
10-Q/A Amended quarterly report Oct 30, 2018 Sep 30, 2018
10-Q Quarterly report Oct 29, 2018 Sep 30, 2018
10-Q Quarterly report Aug 14, 2018 Jun 30, 2018
10-Q Quarterly report Feb 12, 2018 Dec 31, 2017
10-Q Quarterly report Nov 9, 2017 Sep 30, 2017
10-Q Quarterly report Aug 14, 2017 Jun 30, 2017
10-Q/A Amended quarterly report May 11, 2017 Dec 31, 2016
10-Q/A Amended quarterly report May 1, 2017 Dec 31, 2016
10-Q Quarterly report Feb 13, 2017 Dec 31, 2016
10-Q Quarterly report Nov 14, 2016 Sep 30, 2016
10-Q Quarterly report Aug 12, 2016 Jun 30, 2016
10-Q Quarterly report Feb 16, 2016 Dec 31, 2015
10-Q Quarterly report Nov 16, 2015 Sep 30, 2015
10-Q Quarterly report Aug 14, 2015 Jun 30, 2015
10-Q Quarterly report Feb 17, 2015 Dec 31, 2014
10-Q Quarterly report Nov 19, 2014 Sep 30, 2014
10-Q Quarterly report Aug 12, 2014 Jun 30, 2014
10-Q Quarterly report Feb 14, 2014 Dec 31, 2013
10-Q Quarterly report Nov 14, 2013 Sep 30, 2013
10-Q Quarterly report Aug 14, 2013 Jun 30, 2013
10-Q Quarterly report Feb 14, 2013 Dec 31, 2012
10-Q Quarterly report Nov 14, 2012 Sep 30, 2012
10-Q Quarterly report Aug 14, 2012 Jun 30, 2012
10-Q Quarterly report Feb 14, 2012 Dec 31, 2011
10-Q Quarterly report Nov 14, 2011 Sep 30, 2011
10-Q Quarterly report Aug 22, 2011 Jun 30, 2011
10-Q Quarterly report Apr 26, 2011 Mar 31, 2011
10-Q Quarterly report Nov 15, 2010 Sep 30, 2010
10-Q Quarterly report Aug 13, 2010 Jun 30, 2010
10-Q/A Amended quarterly report Aug 4, 2010 Mar 31, 2010
10-Q Quarterly report May 12, 2010 Mar 31, 2010
10-Q Quarterly report Nov 16, 2009 Sep 30, 2009
10-Q Quarterly report Aug 14, 2009 Jun 30, 2009
10-Q Quarterly report May 14, 2009 Mar 31, 2009
10-Q Quarterly report Nov 10, 2008 Sep 30, 2008
10-Q Quarterly report Jul 31, 2008 Jun 30, 2008

Showing 59 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
VTGN (Nasdaq)
Fiscal year ends
March 31
Incorporated in
NV
Headquarters
South San Francisco, CA
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1411685
Former names
Excaliber Enterprises, Ltd. (until Jun 8, 2011)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.